Presence of Concurrent Mutations Is Necessary to Predict Poor Outcomes within the Mutated Subgroup of Metastatic Colorectal Cancer.

Prior studies have resulted in conflicting conclusions on the value of mutations as a prognostic biomarker in metastatic colorectal cancer. In this study, the impact of coexisting mutations with on overall survival was evaluated retrospectively in 433 patients with metastatic colorectal cancer. mutation was found in 16.2% (70/433) of tumors. A systemic univariate and multivariate survival analysis model including age, gender, sidedness of primary tumor, , , , and status showed that mutations were not associated with worse prognosis (multivariate HR = 1.25, 95% CI 0.90-1.73, = 0.18). However, coexisting mutations in and were significantly associated with worse overall survival (multivariate HR = 2.5, 95% CI 1.44-4.36, = 0.001). The median overall survival of patients with coexisting and mutation was 24.2 months, compared to 42.2 months for the rest of the population ( = 0.002). Concurrent and defines a new subgroup of patients of metastatic colorectal cancer with poor clinical outcomes.